(2Z)-2-(4,4-difluoro-1-{4-[(3R)-3-methylpyrrolidin-1-yl]-2-(trifluoromethyl)benzoyl}-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)-N-(2-hydroxyethyl)acetamide | 530091-09-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (2Z)-2-(4,4-difluoro-1-{4-[(3R)-3-methylpyrrolidin-1-yl]-2-(trifluoromethyl)benzoyl}-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)-N-(2-hydroxyethyl)acetamide
• 英文别名: Benzazepinelidene acetamide derivative, 1e；(2Z)-2-[4,4-difluoro-1-[4-[(3R)-3-methylpyrrolidin-1-yl]-2-(trifluoromethyl)benzoyl]-2,3-dihydro-1-benzazepin-5-ylidene]-N-(2-hydroxyethyl)acetamide
• CAS: 530091-09-9
• 化学式: C₂₇H₂₈F₅N₃O₃
• 分子量: 537.53
• InChiKey: WACXYFAARRFXRL-VKZJTJHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  38
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  72.9
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  、 C.I.酸性橙108 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以74%的产率得到(2Z)-2-(4,4-difluoro-1-{4-[(3R)-3-methylpyrrolidin-1-yl]-2-(trifluoromethyl)benzoyl}-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)-N-(2-hydroxyethyl)acetamide
  参考文献：
  名称：

  Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes

  摘要：

  A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives were optimized to achieve potent agonistic activity, both in vitro and in vivo, for the arginine vasopressin V-2 receptor, resulting in the eventual discovery of compound 1g. Molecular modeling of compound 1g with V-2 receptor was also examined to evaluate the binding mode of this series of compounds. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.10.038

文献信息

• 4,4-Difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
  申请人：Koshio Hiroyuki

  公开号：US20050004103A1

  公开（公告）日：2005-01-06

  4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin V 2 activity and are useful for a drug for the treatment of central diabetes insipidus and/or nocturia.

  4,4-二氟-1,2,3,4-四氢-5H-1-苯并氮杂环衍生物具有出色的精氨酸加压素V2活性，可用作治疗中枢性尿崩症和/或夜尿症的药物。
• 4,4-DIFLUORO-1, 2, 3, 4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVES OR SALTS THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1445253B1

  公开（公告）日：2009-08-05
• US7169772B2
  申请人：——

  公开号：US7169772B2

  公开（公告）日：2007-01-30